Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

Sooman, Linda; Lennartsson, Johan; Gullbo, Joachim; Bergqvist, Michael; Tsakonas, Georgios; Johansson, Fredrik; Edqvist, Per-Henrik; Pontén, Fredrik; Jaiswal, Archita; Navani, Sanjay; Alafuzoff, Irina; Popova, Svetlana; Blomquist, Erik; Ekman, Simon
September 2013
Medical Oncology;Sep2013, Vol. 30 Issue 3, p1
Academic Journal
No abstract available.


Related Articles

  • p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Yeung, Yiu; Bryce, Nicole; Adams, Seray; Braidy, Nady; Konayagi, Mari; McDonald, Kerrie; Teo, Charles; Guillemin, Gilles; Grewal, Thomas; Munoz, Lenka // Journal of Neuro-Oncology;Aug2012, Vol. 109 Issue 1, p35 

    Increasing evidence suggests that an inflammatory microenvironment promotes invasion by glioblastoma (GBM) cells. Together with p38 mitogen-activated protein kinase (MAPK) activation being regarded as promoting inflammation, we hypothesized that elevated inflammatory cytokine secretion and p38...

  • Changes in Signaling Pathways Induced by Vandetanib in a Human Medullary Thyroid Carcinoma Model, as Analyzed by Reverse Phase Protein Array. Broutin, Sophie; Commo, Frédéric; De Koning, Leanne; Marty-Prouvost, Bérengère; Lacroix, Ludovic; Talbot, Monique; Caillou, Bernard; Dubois, Thierry; Ryan, Anderson J.; Dupuy, Corinne; Schlumberger, Martin; Bidart, Jean-Michel // Thyroid;Jan2014, Vol. 24 Issue 1, p43 

    Background: Medullary thyroid carcinoma (MTC) is a rare tumor that is caused by activating mutations in the proto-oncogene RET. Vandetanib, a tyrosine-kinase inhibitor, has been recently approved to treat adult patients with metastatic MTC. The aim of this study was to investigate changes in...

  • Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger, Sebastian; Flentje, Michael; Djuzenova, Cholpon S. // Radiation Oncology;10/24/2015, Vol. 10 Issue 1, p1 

    Background: The mitogen-activated protein kinases (MAPK) and the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are intertwined on various levels and simultaneous inhibition reduces tumorsize and prolonges survival synergistically. Furthermore,...

  • Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. Sooman, Linda; Ekman, Simon; Andersson, Claes; Kultima, Hanna; Isaksson, Anders; Johansson, Fredrik; Bergqvist, Michael; Blomquist, Erik; Lennartsson, Johan; Gullbo, Joachim // Cancer Chemotherapy & Pharmacology;Aug2013, Vol. 72 Issue 2, p329 

    Purpose: The current treatment strategies for glioblastoma have limited health and survival benefits for the patients. A common obstacle in the treatment is chemoresistance. A possible strategy to evade this problem may be to combine chemotherapeutic drugs with agents inhibiting resistance...

  • KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis. Seon Rang Woo; Yunhee Ham; Wonyoung Kang; Heekyoung Yang; Sujong Kim,; Juyoun Jin; Kyeung Min Joo; Do-Hyun Nam // BioMed Research International;2014, Vol. 2014, p1 

    Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy. Nevertheless, majority of glioblastoma patients have recurrence from resistance to the cytotoxic conventional therapies. We examined combinational effects of KML001, an arsenic...

  • Effect of Rosehip (Rosa canina) Extracts on Human Brain Tumor Cell Proliferation and Apoptosis. Cagle, Patrice; Idassi, Ombeni; Carpenter, Janelle; Minor, Radiah; Goktepe, Ipek; Martin, Patrick // Journal of Cancer Therapy;Oct2012, Vol. 3 Issue 5, p534 

    Rosehips are blossoms from the wild rose (Rosa canina) and are commonly used as an herbal remedy. Previous reports have shown that extracts made from rosehip plants are able to reduce cell proliferation of cancer cells. In this study, we investigated the efficacy of rosehip extracts in...

  • Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Atefi, Mohammad; Bjoern Titz; Avramis, Earl; Charles Ng; Wong, Deborah J. L.; Lassen, Amanda; Cerniglia, Michael; Escuin-Ordinas, Helena; Foulad, David; Comin-Anduix, Begonya; Graeber, Thomas G.; Ribas, Antoni // Molecular Cancer;2015, Vol. 14 Issue 1, p1 

    Background: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting...

  • Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Andersson, Mattias K.; Åman, Pierre // Cancer Cell International;2008, Vol. 8, Special section p1 

    Background: Tyrosine kinase inhibitors (TKIs) have gained much attention in recent years as targeted agents for the treatment of a wide range of human cancers. We have investigated the effect of the TKIs gefitinib and vandetanib on tumor cell lines derived from Ewing sarcoma, a highly malignant...

  • Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. Chheda, Milan; Wen, Patrick; Hochberg, Fred; Chi, Andrew; Drappatz, Jan; Eichler, April; Yang, Daniel; Beroukhim, Rameen; Norden, Andrew; Gerstner, Elizabeth; Betensky, Rebecca; Batchelor, Tracy // Journal of Neuro-Oncology;Feb2015, Vol. 121 Issue 3, p627 

    Targeting specific molecular alterations in glioblastoma (GBM) might more effectively kill tumor cells and increase survival. Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. Sirolimus inhibits mammalian target of rapamycin (mTOR), a member...

  • Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Dong, Song; Zhang, Xu-Chao; Cheng, Hua; Zhu, Jian-Quan; Chen, Zhi-Hong; Zhang, Yi-Fang; Xie, Zhi; Wu, Yi-Long // Cancer Chemotherapy & Pharmacology;Nov2012, Vol. 70 Issue 5, p707 

    Purpose: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is considered as one of the most important treatments for patients with advanced non-small-cell lung cancer (NSCLC). However, not all patients benefit from this therapy because of primary or acquired...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics